Sign in

Peter Keach

Managing Director and Equity Research Analyst at Piper Sandler & Co.

Peter Keach is a Managing Director and Equity Research Analyst at Piper Sandler Companies, specializing in the coverage of specialty pharmaceuticals and biotechnology firms. He covers notable companies such as Collegium Pharmaceutical, Amphastar Pharmaceuticals, Corcept Therapeutics, and ANI Pharmaceuticals, with his research recognized for its thoroughness and analytical rigor. With over a decade in equity research, Keach joined Piper Sandler in 2017 after serving as an analyst at investment firms like Guggenheim Securities and Jefferies, consistently earning strong ratings on platforms such as TipRanks, where he maintains a success rate above 55% and double-digit average returns on his recommendations. He is FINRA registered, holding Series 7, 63, 86, and 87 licenses, and is known for his actionable research and sector expertise.

Peter Keach's questions to Savers Value Village (SVV) leadership

Question · Q2 2025

Sarah on for Peter Keach asked about the specific drivers behind the 'value selection' strength in both the U.S. and Canada and any related processing improvements.

Answer

COO Jubran Tanious highlighted the company's continuous improvement in precisely managing seasonal inventory transitions to match customer preferences. CEO Mark Walsh added that high inventory turns (15x a year) and a focus on freshness and value are core to their model and what their 'thrifter' customers demand.

Ask follow-up questions

Fintool

Fintool can predict Savers Value Village logo SVV's earnings beat/miss a week before the call

Let Fintool AI Agent track Peter Keach for you

Get briefed when they ask questions on calls

Best AI Agent for Equity Research

Performance on expert-authored financial analysis tasks

Fintool-v490%
Claude Sonnet 4.555.3%
o348.3%
GPT 546.9%
Grok 440.3%
Qwen 3 Max32.7%

Try Fintool for free